J&J completes Novira Therapeutics acquisition

NEW BRUNSWICK, N.J. — Johnson & Johnson on Friday announced that it had completed its acquisition of clinical biopharma company Novira Therapeutics. The terms of the transaction, which was announced Nov. 4, were not disclosed. 

 

Novira, which develops innovative treatments for chronic hepatitis B, will now be part of Janssen Pharmaceuticals’ Infectious Diseases and Vaccines Therapeutic Area. The lead candidate among Novira’s portfolio is NVR 3-778. 

 

“We are exploring several approaches in pursuit of a functional cure for this insidious disease,” Janssen’s global head of research and development William Hait said. “Bringing together NVR 3-778 with our own internal discoveries we will leverage our vast experience in viral diseases to develop potentially transformational medicines for HBV patients.”